Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020


  • Published On : May-2015 |
  • Pages : 197 Pages |
  • Format :

Biopharmaceuticals are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes. Biopharmaceutical production involves the usage of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments. Biopharmaceuticals have lead to enhancement in the quality of healthcare and has improved the quality of life of patients. Various biopharmaceuticals used for treating such diseases are monoclonal antibodies, erythropoietin, growth hormones, recombinant proteins, recombinant human insulin, purified proteins, interferon, vaccines and other biopharmaceuticals. However, high costs of biopharmaceuticals, entry of low-cost biosimilars, and risk of side-effects posed by biopharmaceuticals act as restraints for the biopharmaceuticals market.

In terms of value, North America dominates the biopharmaceuticals market. This is due to rising research and development investments and increasing technological advancements in biopharmaceuticals in the region. The market in Asia is expected to experience a high growth rate in the near future. This is due to improving the quality of healthcare and increasing adoption of biopharmaceuticals by physicians, drug wholesalers, pharmacies, and patients in the region.

Various factors such as increasing chronic diseases, aging population, and technological advancements in biopharmaceuticals along with increasing investment in research and development by various companies has lead to the growth of the global biopharmaceuticals market. However, high costs of biopharmaceuticals, the risk of side–effects, and availability of low-cost biosimilars are restraining the growth of the global market for biopharmaceuticals.

This report provides in-depth analysis and estimation of the biopharmaceuticals market for the period 2014–2020, considering 2013 as the base year for the calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and strategic developments has been provided in the report. The biopharmaceuticals market is categorized on the basis of type, application, and geography. Based on type, the global biopharmaceuticals market can be classified as monoclonal antibodies, erythropoietin, granulocyte colony stimulating factor, purified proteins, recombinant proteins, recombinant human insulin, interferon, growth hormones, vaccines, and other biopharmaceuticals. Based on the therapeutic application, the global biopharmaceuticals can be classified as oncology, metabolic disorders, neurological disorders, cardiovascular diseases, inflammatory and infectious diseases, and other rare diseases.

In the geographical analysis, the report identifies and analyses market size and forecast of North America, Europe, Asia, and Rest of the World (RoW). North America is further segmented into the U.S., and Canada; Europe into the U.K., Germany, France, Italy, Spain, and Russia;  Asia into China, Japan, and India; and RoW into Australia and Brazil.

Biopharmaceuticals are pharmaceutical products which are produced through biotechnology methods involving recombinant DNA techniques, hybridoma techniques, and purification processes. Biopharmaceutical production involves the use of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments. It has lead to enhancement of the quality of healthcare and has improved the quality of life of patients. Various biopharmaceuticals used for treating such diseases are monoclonal antibodies, erythropoietin, growth hormones, recombinant proteins, recombinant human insulin, purified proteins, interferon, vaccines, and other biopharmaceuticals. Factors such as high costs of biopharmaceuticals, entry of low-cost biosimilars, and risk of side-effects posed by biopharmaceuticals act as major restraints for the biopharmaceuticals market. The global biopharmaceuticals market was valued at US$ 161,851.6 Mn in 2014 and is expected to expand at a CAGR of 9.4% to reach US$ 278,232.9 Mn by 2020.

North America is the largest market for the biopharmaceuticals. This is due to technological advancements in the region. In terms of types, monoclonal antibodies are the fastest growing segment. In terms of therapeutic application, oncology is the largest segment in the biopharmaceuticals market. Biopharmaceuticals have wide applications in the pharmaceutical industry.

The North America biopharmaceuticals market was valued at US$ 64,681.3 Mn in 2014 and is expected to reach US$ 111,598.2 Mn by 2020 at a CAGR of 9.5% over the forecast period. One of the latest trends in the global biopharmaceuticals market is outsourcing, wherein biopharmaceutical companies enter into partnerships with contract manufacturing organizations (CMOs) to produce biopharmaceutical drug substances. This reduces the overall investment to launch a new product in the market and helps gain market access with ease. 

Pfizer, Inc., F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Sanofi, Amgen Inc., AbbVie Inc., Merck & Co., Inc., Biogen Idec, Bayer AG, Eli Lilly and Company, and Novartis AG are some of the leading players in the global market for biopharmaceuticals. Some of the other players in the biopharmaceuticals market are GlaxoSmithKline Plc, Bristol-Myers Squibb Company, AstraZeneca PLC, and Abbott Laboratories.

biopharmaceutical-market

Some of the major players in the Biopharmaceuticals market:

  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG.
  • Johnson & Johnson Services, Inc.
  • Sanofi, Amgen Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Biogen Idec.
  • Bayer AG.
  • Eli Lilly and Company.
  • Novartis AG GlaxoSmithKline Plc.
  • Bristol-Myers Squibb Company.
  • AstraZeneca PLC.
  • Abbott Laboratories.
  • Other

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Chapter 1 Preface 14

1.1 Report Description 14

1.2 Research Methodology 15

1.3 Assumptions 15

Chapter 2 Market Synopsis 17

Chapter 3 Porter’s Five Forces Analysis 19

3.1 Bargaining Power of Suppliers 19

3.2 Bargaining Power of Buyers 20

3.3 Threat of New Entrants 20

3.4 Threat of Substitutes 21

3.5 Intensity of Rivalry 21

Chapter 4 Market Overview 22

4.1 Market Definition 22

4.2 Market Drivers 26

      4.2.1 Increasing aging population 26

      4.2.2 Rising cases of chronic diseases 27

      4.2.3 Technological advancements 28

      4.2.4 Increasing R&D investments 28

4.3 Impact Analysis of Market Drivers 30

4.4 Restraints 31

      4.4.1 High costs of biopharmaceuticals 31

      4.4.2 Entry of low-cost biosimilars 31

      4.4.3 Risk of side effects posed by biopharmaceutical drugs 32

4.5 Impact Analysis of Market Restraints 33

4.6 Opportunities 34

      4.6.1 Diseases with high unmet needs 34

      4.6.2 Emerging markets 34

      4.6.3 Increasing new pipeline products 35

4.7 Trends 36

      4.7.1 Outsourcing trends 36

Chapter 5 Global Market Size and Forecast 37

Chapter 6 Market Size and Forecast by Type 43

6.1 Monoclonal Antibodies 43

6.2 Recombinant Proteins 45

6.3 Granulocyte-Colony Stimulating Factor (G-CSF) 47

6.4 Interferons 49

6.5 Recombinant Human Insulin 51

6.6 Erythropoietin 53

6.7 Vaccines 55

6.8 Growth Hormones 57

6.9 Purified Proteins 59

6.10 Others 61

Chapter 7 Market Size and Forecast by Therapeutic Application 64

7.1 Metabolic Disorders 64

7.2 Oncology 66

7.3 Neurological Disorders 68

7.4 Cardiovascular Diseases 70

7.5 Inflammatory and Infectious Diseases 72

7.6 Others 74

Chapter 8 Market Size and Forecast by Geography 77

8.1 North America 77

      8.1.1 Scenario in the U.S. 79

      8.1.2 Scenario in Canada 84

8.2 Europe 90

      8.2.1 Scenario in the U.K. 93

      8.2.2 Scenario in Germany 98

      8.2.3 Scenario in France 103

      8.2.4 Scenario in Russia 108

      8.2.5 Scenario in Italy 114

      8.2.6 Scenario in Spain 118

8.3 Asia 123

      8.3.1 Scenario in Japan 126

      8.3.2 Scenario in China 130

      8.3.3 Scenario in India 135

8.4 Rest of the World 140

      8.4.1 Scenario in Brazil 142

      8.4.2 Scenario in Australia 147

Chapter 9 Competitive Scenario 153

9.1 Competitive Benchmarking 153

9.2 Company Share Analysis 155

Chapter 10 Company Profiles 157

10.1 Abbott Laboratories 157

      10.1.1 Company overview 157

      10.1.2 Products and services 158

      10.1.3 Financial performance 158

      10.1.4 Key developments 159

10.2 Pfizer, Inc. 160

      10.2.1 Company overview 160

      10.2.2 Products and services 160

      10.2.3 Financial performance 161

      10.2.4 Key developments 161

10.3 Eli Lilly and Company 162

      10.3.1 Company overview 162

      10.3.2 Products and services 162

      10.3.3 Financial performance 163

      10.3.4 Key developments 163

10.4 Sanofi 164

      10.4.1 Company overview 164

      10.4.2 Products and services 164

      10.4.3 Financial performance 165

      10.4.4 Key developments 166

10.5 AbbVie Inc. 167

      10.5.1 Company overview 167

      10.5.2 Products and segments 167

      10.5.3 Financial performance 168

      10.5.4 Key developments 168

10.6 Novartis AG 169

      10.6.1 Company overview 169

      10.6.2 Products and services 170

      10.6.3 Financial performance 170

      10.6.4 Key developments 171

10.7 AstraZeneca plc 172

      10.7.1 Company overview 172

      10.7.2 Products and services 172

      10.7.3 Financial performance 173

      10.7.4 Key developments 173

10.8 Amgen, Inc. 175

      10.8.1 Company Overview 175

      10.8.2 Product and Services 175

      10.8.3 Financial Performance 176

      10.8.4 Recent Developments 176

10.9 Biogen Idec 178

      10.9.1 Company Overview 178

      10.9.2 Product and Services 178

      10.9.3 Financial Performance 179

      10.9.4 Recent Developments 179

10.10 GlaxoSmithKline Plc 182

      10.10.1 Company overview 182

      10.10.2 Products and services 182

      10.10.3 Financial performance 183

      10.10.4 Key developments 183

10.11 Bristol-Myers Squibb Company 185

      10.11.1 Company overview 185

      10.11.2 Products and services 185

      10.11.3 Financial performance 186

      10.11.4 Key developments 186

10.12 Bayer AG 187

      10.12.1 Company overview 187

      10.12.2 Products and segments 187

      10.12.3 Financial performance 188

      10.12.4 Key developments 188

10.13 Merck & Co., Inc. 190

      10.13.1 Company overview 190

      10.13.2 Products and services 190

      10.13.3 Financial performance 191

      10.13.4 Key developments 191

10.14 F. Hoffmann-La Roche, Ltd. 192

      10.14.1 Company overview 192

      10.14.2 Products and services 192

      10.14.3 Financial performance 193

      10.14.4 Key developments 193

10.15 Johnson & Johnson Services, Inc. 195

      10.15.1 Overview 195

      10.15.2 Products and Segments 195

      10.15.3 Financial Performance 196

      10.15.4 Strategic Development 196


List of Table

TABLE 1 Market snapshot: biopharmaceuticals market, 2014 and 2020 18

TABLE 2 Drivers for biopharmaceutical market: Impact analysis 30

TABLE 3 Restraints for biopharmaceutical market: Impact analysis 33

TABLE 4 Global biopharmaceuticals market size, by region, 2010 – 2013 (USD Mn) 37

TABLE 5 Global biopharmaceuticals market size, by region, 2014 – 2020 (USD Mn) 38

TABLE 6 Global biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 39

TABLE 7 Global biopharmaceuticals market size, by usage, 2014 – 2020 (USD Mn) 40

TABLE 8 Global biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 41

TABLE 9 Global biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 42

TABLE 10 Global monoclonal antibodies market size, by region, 2010 – 2013 (USD Mn) 44

TABLE 11 Global monoclonal antibody market size, by region, 2014 – 2020 (USD Mn) 45

TABLE 12 Global recombinant proteins market size, by region, 2010 – 2013 (USD Mn) 46

TABLE 13 Global recombinant proteins market size, by region, 2014 – 2020 (USD Mn) 47

TABLE 14 Global granulocyte-colony stimulating factor market size, by region, 2010 – 2013 (USD Mn) 48

TABLE 15 Global granulocyte-colony stimulating factor market size, by region, 2014 – 2020 (USD Mn) 49

TABLE 16 Global interferons market size, by region, 2010 – 2013 (USD Mn) 50

TABLE 17 Global interferons market size, by region, 2014 – 2020 (USD Mn) 51

TABLE 18 Global recombinant human insulin market size, by region, 2010 – 2013 (USD Mn)  52

TABLE 19 Global recombinant human insulin market size, by region, 2014 – 2020 (USD Mn)  53

TABLE 20 Global erythropoietin market size, by region, 2010 – 2013 (USD Mn) 54

TABLE 21 Global erythropoietin market size, by region, 2014 – 2020 (USD Mn) 55

TABLE 22 Global vaccines market size, by region, 2010 – 2013 (USD Mn) 56

TABLE 23 Global vaccines market size, by region, 2014 – 2020 (USD Mn) 57

TABLE 24 Global growth hormones market size, by region, 2010 – 2013 (USD Mn) 58

TABLE 25 Global growth hormones market size, by region, 2014 – 2020 (USD Mn) 59

TABLE 26 Global purified proteins market size, by region, 2010 – 2013 (USD Mn) 60

TABLE 27 Global purified proteins market size, by region, 2014 – 2020 (USD Mn) 61

TABLE 28 Global other market size, by region, 2010 – 2013 (USD Mn) 62

TABLE 29 Global other market size, by region, 2014 – 2020 (USD Mn) 63

TABLE 30 Global metabolic disorders market size, by region, 2010 – 2013 (USD Mn) 65

TABLE 31 Global metabolic disorders market size, by region, 2014 – 2020 (USD Mn) 66

TABLE 32 Global oncology market size, by region, 2010 – 2013 (USD Mn) 67

TABLE 33 Global oncology market size, by region, 2014 – 2020 (USD Mn) 68

TABLE 34 Global neurological disorders market size, by region, 2010 – 2013 (USD Mn) 69

TABLE 35 Global neurological disorders market size, by region, 2014 – 2020 (USD Mn) 70

TABLE 36 Global cardiovascular diseases market size, by region, 2010 – 2013 (USD Mn) 71

TABLE 37 Global cardiovascular diseases market size, by region, 2014 – 2020 (USD Mn) 72

TABLE 38 Global inflammatory and infectious diseases market size, by region, 2010 – 2013 (USD Mn) 73

TABLE 39 Global inflammatory and infectious diseases market size, by region, 2014 – 2020 (USD Mn) 74

TABLE 40 Global others market size, by region, 2010 – 2013 (USD Mn) 75

TABLE 41 Global others market size, by region, 2014 – 2020 (USD Mn) 76

TABLE 42 The North American biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn) 78

TABLE 43 The North American biopharmaceuticals market size, by country, 2014 – 2020 (USD Mn) 79

TABLE 44 The U.S. biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 81

TABLE 45 The U.S. biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 82

TABLE 46 The U.S. biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 83

TABLE 47 The U.S. biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 84

TABLE 48 Canadian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 86

TABLE 49 Canadian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 87

TABLE 50 The Canadian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 88

TABLE 51 Canadian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 89

TABLE 52 The European biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn)  92

TABLE 53 The European biopharmaceuticals market size, by country, 2014 – 2020 (USD Mn)  93

TABLE 54 The U.K. biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 95

TABLE 55 The U.K. biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 96

TABLE 56 The U.K. biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 97

TABLE 57 The U.K. biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 98

TABLE 58 German biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 100

TABLE 59 German biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 101

TABLE 60 German biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 102

TABLE 61 German biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 103

TABLE 62 French biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 105

TABLE 63 French biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 106

TABLE 64 French biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 107

TABLE 65 French biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 108

TABLE 66 Russian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 110

TABLE 67 Russian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 111

TABLE 68 Russian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 112

TABLE 69 Russian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 113

TABLE 70 Italian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 115

TABLE 71 Italian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 116

TABLE 72 Italian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 117

TABLE 73 Italian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 118

TABLE 74 Spanish biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 120

TABLE 75 Spanish biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 121

TABLE 76 Spain biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 122

TABLE 77 Spain biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 123

TABLE 78 The Asian biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn) 125

TABLE 79 The Asian biopharmaceuticals market size, by region, 2014 – 2020 (USD Mn) 125

TABLE 80 Japanese biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 127

TABLE 81 Japanese biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 128

TABLE 82 Japanese biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 129

TABLE 83 Japanese biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 130

TABLE 84 Chinese biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 132

TABLE 85 Chinese biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 133

TABLE 86 Chinese biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 134

TABLE 87 Chinese biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 135

TABLE 88 Indian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 137

TABLE 89 Indian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 138

TABLE 90 Indian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 139

TABLE 91 Indian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 140

TABLE 92 The Rest of the World biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn) 141

TABLE 93 Global biopharmaceuticals market size, by region, 2014 – 2020 (USD Mn) 142

TABLE 94 Brazilian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 144

TABLE 95 Brazilian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 145

TABLE 96 Brazilian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 146

TABLE 97 Brazilian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 147

TABLE 98 Australian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 149

TABLE 99 Australian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 150

TABLE 100 Australian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 151

TABLE 101 Australian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 152

TABLE 102 Product categories of Abbott Laboratories 158

TABLE 103 Product category of Pfizer, Inc. 160

TABLE 104 Product category of Eli Lilly and Company 162

TABLE 105 Product categories of Sanofi 164

TABLE 106 Product segment of AbbVie Inc. 167

TABLE 107 Novartis AG’s product categories 170

TABLE 108 AstraZeneca plc’s product categories 172

TABLE 109 Amgen, Inc. product category 175

TABLE 110 Biogen Idec major therapies and their uses 178

TABLE 111 Major product categories of GlaxoSmithKline Plc 182

TABLE 112 Major product categories of Bristol-Myers Squibb Company 185

TABLE 113 Product categories of Bayer AG 187

TABLE 114 Major product categories of Merck & Co., Inc. 190

TABLE 115 Major product categories of Roche 192

TABLE 116 Johnson & Johnson Services, Inc.’s Product Categories 195


List of Figures

FIG. 1 Biopharmaceuticals market: Porter’s five forces analysis 19

FIG. 2 Categorization of Biopharmaceuticals by Type 24

FIG. 3 Categorization of Biopharmaceuticals by Therapeutic Application 25

FIG. 4 Population aged 60 years and above in major countries, 2000 – 2050 26

FIG. 5 Comparison of percentage of Total biopharmaceutical revenues generation by major pharmaceutical companies, 2000 and 2012 29

FIG. 6 Global biopharmaceuticals market share, by region, by value, 2013 37

FIG. 7 Global biopharmaceuticals market share, by type, by value, 2013 39

FIG. 8 Global biopharmaceuticals market share, by therapeutic application, 2013 41

FIG. 9 Global monoclonal antibodies market share, by region, by value, 2013 44

FIG. 10 Global recombinant proteins market share, by region, by value, 2013 46

FIG. 11 Global granulocyte-colony stimulating factor market share, by region, by value, 2013  48

FIG. 12 Global interferons market share, by region, by value, 2013 50

FIG. 13 Global recombinant human insulin market share, by region, by value, 2013 52

FIG. 14 Global erythropoietin market share, by region, by value, 2013 54

FIG. 15 Global vaccines market share, by region, by value, 2013 56

FIG. 16 Global growth hormones market share, by region, by value, 2013 58

FIG. 17 Global purified proteins market share, by region, by value, 2013 60

FIG. 18 Global other market share, by region, by value, 2013 62

FIG. 19 Global metabolic disorders market share, by region, by value, 2013 65

FIG. 20 Global oncology market share, by region, by value, 2013 67

FIG. 21 Global neurological disorders market share, by region, by value, 2013 69

FIG. 22 Global cardiovascular diseases market share, by region, by value, 2013 71

FIG. 23 Global inflammatory and infectious diseases market share, by region, by value, 2013  73

FIG. 24 Global others market share, by region, by value, 2013 75

FIG. 25 North America biopharmaceuticals market share, by country, by value, 2013 78

FIG. 26 The U.S. biopharmaceuticals market share, by type, by value, 2013 80

FIG. 27 The U.S. biopharmaceuticals market share, by therapeutic application, by value, 2013  83

FIG. 28 Canadian biopharmaceuticals market share, by type, by value, 2013 85

FIG. 29 Canadian biopharmaceuticals market share, by therapeutic application, by value, 2013  88

FIG. 30 Europe biopharmaceuticals market share, by country, by value, 2013 91

FIG. 31 The U.K. biopharmaceuticals market share, by type, by value, 2013 94

FIG. 32 The U.K. biopharmaceuticals market share, by therapeutic application, by value, 2013  97

FIG. 33 German biopharmaceuticals market share, by type, by value, 2013 99

FIG. 34 German biopharmaceuticals market share, by therapeutic application, by value, 2013  102

FIG. 35 French biopharmaceuticals market share, by type, by value, 2013 104

FIG. 36 French biopharmaceuticals market share, by therapeutic application, by value, 2013  107

FIG. 37 Russian biopharmaceuticals market share, by type, by value, 2013 109

FIG. 38 Russian biopharmaceuticals market share, by therapeutic application, by value, 2013  112

FIG. 39 Italian biopharmaceuticals market share, by type, by value, 2013 114

FIG. 40 Italian biopharmaceuticals market share, by therapeutic application, by value, 2013 117

FIG. 41 Spanish biopharmaceuticals market share, by type, by value, 2013 119

FIG. 42 Spain biopharmaceuticals market share, by therapeutic application, by value, 2013 122

FIG. 43 Asian biopharmaceuticals market share, by country, by value, 2013 124

FIG. 44 Japanese biopharmaceuticals market share, by type, by value, 2013 126

FIG. 45 Japanese biopharmaceuticals market share, by therapeutic application, by value, 2013  129

FIG. 46 Chinese biopharmaceuticals market share, by type, by value, 2013 131

FIG. 47 Chinese biopharmaceuticals market share, by therapeutic application, by value, 2013  134

FIG. 48 Indian biopharmaceuticals market share, by type, by value, 2013 136

FIG. 49 Indian biopharmaceuticals market share, by therapeutic application, by value, 2013 139

FIG. 50 Rest of the World biopharmaceuticals market share, by country, by value, 2013 141

FIG. 51 Brazilian biopharmaceuticals market share, by type, by value, 2013 143

FIG. 52 Brazilian biopharmaceuticals market share, by therapeutic application, by value, 2013  146

FIG. 53 Australian biopharmaceuticals market share, by type, by value, 2013 148

FIG. 54 Australian biopharmaceuticals market share, by therapeutic application, by value, 2013  151

FIG. 55 Competitive landscape of biopharmaceuticals market, 2014 153

FIG. 56 Global Biopharmaceuticals market, by company 2014 (% share) 155

FIG. 57 Abbott Laboratories net sales and net earnings, 2012 – 2014 (USD Mn) 158

FIG. 58 Pfizer, Inc.’s Total revenue and net income, 2012 – 2014 (USD Mn) 161

FIG. 59 Eli Lilly and Company’s revenue and net income, 2012 – 2014 (USD Mn) 163

FIG. 60 Sanofi’s net sales and net income, 2012 – 2014 (USD Mn) 165

FIG. 61 AbbVie, Inc.’s net sales and net earnings, 2012 – 2014 (USD Mn) 168

FIG. 62 Novartis AG’s net sales and net income, 2012 – 2014 (USD Mn) 170

FIG. 63 AstraZeneca plc revenue and profit, 2012 – 2014 (USD Mn) 173

FIG. 64 Amgen, Inc. revenue and net income 2012 – 2014 (USD Mn) 176

FIG. 65 Biogen Idec revenue and net income 2012 – 2014 (USD Mn) 179

FIG. 66 GlaxoSmithKline plc’s turnover and profit, 2012 – 2014 (USD Mn) 183

FIG. 67 Bristol-Myers Squibb Company’s total revenue and net earnings, 2012 – 2014 (USD Mn) 186

FIG. 68 Bayer AG’s net sales and net income, 2011 – 2013 (USD Mn) 188

FIG. 69 Merck & Co., Inc.’s sales and net income, 2012 – 2014 (USD Mn) 191

FIG. 70 Roche’s sales and net income, 2012 – 2014 (USD Mn) 193

FIG. 71 Johnson & Johnson Services, Inc., net sales and net earnings, 2012 – 2014 (USD Mn) 196

Back To Top